Two therapeutic challenges: Periocular and genital vitiligo in children successfully treated with pimecrolimus cream

International Journal of Dermatology

Volumn 46, Issue 9, 2007, Pages 986-989

  Souza Leite, Rubens Marcelo ^a,b   Craveiro Leite, Adriana Aragão ^a  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b SMHN Q2 ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; PIMECROLIMUS;

ARTICLE; CASE REPORT; CHILDHOOD DISEASE; CLINICAL FEATURE; DRUG CHOICE; HUMAN; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; REMISSION; SCHOOL CHILD; SKIN PIGMENTATION; VITILIGO;

ADMINISTRATION, TOPICAL; CHILD; EYELIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PENIS; REMISSION INDUCTION; SKIN; TACROLIMUS; VITILIGO;

EID: 34548544626     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03282.x     Document Type: Article

References (21)

1. Lerner AB. Vitiligo. J Invest Dermatol 1959; 32: 285-310.
2. Osborne GE, Francis ND, Bunker CB. Synchronous onset of penile lichen planus and vitiligo. Br J Dermatol, 2000; 143: 218-219.
3. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci 2005; 39: 137-146.
4. Schaffer JV, Bologna JL. The treatment of hypopigmentation in children. Clin Dermatol 2003; 21: 296-310.
5. Njoo MD, Westenhof W, Bos D, et al. The development of guidelines for the treatment of vitiligo. Arch Dermatol 1999:135: 1514-1521.
6. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 67-68.
7. Grimes PE, Soriano T, Dytoc M. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002 ; 47: 789-791.
8. Coskun B, Saral Y, Turqut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
9. Odom RB, James WD, Berger TG. Andrew's Diseases of the Skin: Clinical Dermatology, 9th edn. Philadelphia, PA: W.B. Saunders Company, 2000: 1065-1066.
10. Moelmann GE, Krass P, Halaban R, et al. On the subject of serum antibodies to melanocytes in vitiligo. J Invet Dermatol 1985; 84: 333.
11. Yu HS, Chang KL, Yu CL, et al. Alterations in IL-6, IL-8, GM-CSF, TNF-, and IFN-release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997; 108: 527-529.
12. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptors and the types of activity of vitiligo. J Dermatol 1997; 24: 561-563.
13. Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci, 1999; 21: 59-62.
14. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
15. Consensus Conference Management of atopic dermatitis in children. Recommendations (short version). Eur J Dermatol 2005; 15: 215-230.
16. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs. 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 651-654.
17. Grimes PE. Therapeutic trends for the treatment of vitiligo. Cosmet Dermatol 2002; 15: 21-25.
18. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13: 136-142.
19. Papp K, Staab D, Harper J, et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol 2004; 43: 978-983.
20. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus-an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-730.
21. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis - a multicenter, 3-week, open-label study. Pediatr Dermatol 2005; 22: 465-471.